
Helus Pharma (NASDAQ: HELP; Cboe CA: HELP) has announced positive topline results from APPROACH, its Phase 3 pivotal study evaluating HLP003 (deuterated psilocin), as an adjunctive treatment for adults with major depressive disorder (MDD).
According to Helus, HLP003 achieved statistically significant and clinically meaningful results in the primary, key secondary and other secondary endpoints starting as early as Day 2 and these were maintained at all time.
In a statement, Michael Halstead, CEO of Helus, commented, “The large unmet need for patients with major depressive disorder who continue to experience persistent symptoms underscores the importance of new rapid-acting and well-tolerated adjunctive treatment options. We believe these data demonstrate a therapeutic profile that has the potential to meaningfully improve outcomes for patients and strengthen our momentum as we continue to progress HLP003 toward regulatory approval and potential commercialization.”






